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Abstract 
 
“Oh no, I feel uncomfortable with blood, I don’t know if I want to take the HIV test!”   
 
This is a general attitude towards HIV/AIDS inside a voluntary testing and counselling 
(VCT) environment and it is enhanced by numerous superstitions and misconceptions 
regarding HIV/AIDS which still occur in a South African context.  Yet there is an alternative, 
approved test for HIV/AIDS available which does not require a blood sample. 
 
Testing for the presence of HIV/AIDS by means of an oral specimen has been used for more 
than 10 years, while the rapid version thereof received official endorsement in the USA in 
2004.  Although the oral fluid HIV testing option is utilized in SA, oral fluid tests have still to 
be used in an official capacity.  No policy, guidelines or legislation regarding any aspect of 
oral fluid HIV testing currently exists in SA.  As a result, this alternative HIV testing method 
is not well-known among the general South African public. 
 
The aim of this research paper will be to raise - and positively influence - the profile and 
image of oral HIV testing as an attractive alternative to HIV testing that requires a blood 
specimen.  The foundation for this will be laid by proving that the lack of the need for a blood 
specimen in oral fluid HIV testing positively influences testing for HIV.   
 
This research project will further suggest a specific promotional strategy for oral testing with 
the aim of convincing more individuals to test for HIV.  This strategy will be based on its 
distinguishing characteristic – namely the absence of blood – and entails the following:  A 
poster campaign will be suggested to create awareness and promote these tests as a more 
“user friendly” version of HIV testing.  At ground level the strategy will be carried out by 
setting up mobile HIV/AIDS testing units, specializing in oral fluid HIV testing.  Moreover 
certain guidelines will be suggested for oral test administration. 
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Opsomming 
 
“Ai toggie, ek is ongemaklik met bloed, ek weet nie of ek die Vigs-toets gaan doen nie!”   
 
Hierdie is ’n algemene gevoel teenoor MIV/Vigs toetsing binne ’n vrywillige berading en 
toetsing (VCT) milieu, en word aangehelp deur die vele wanopvattings en bygelowe rondom 
MIV/Vigs wat steeds in ’n Suid-Afrikaanse konteks voorkom.  Tog is daar ’n alternatiewe, 
goedgekeurde toets vir MIV/Vigs beskikbaar wat nie ’n bloedmonster vereis nie. 
 
Die gebruik van orale monsters om vir die aanwesigheid van MIV/Vigs te toets, is reeds meer 
as 10 jaar in gebruik, terwyl die gebruik van rapid orale monster toetse in 2004 in Amerika 
amptelike goedkeuring ontvang het.  Hoewel hierdie orale toetse wel in Suid-Afrika gebruik 
word, is daar geen amptelike beleid of riglyne wat die gebruik, aanwending of verspreiding 
van hierdie toetse beheer of reguleer nie – met die gevolg dat hierdie toetse as ’n alternatief 
tot konvensionele MIV toetse grotendeels in die publieke oog onbekend is. 
 
Die hoofdoelwit van hierdie navorsingsprojek is om die openbare beeld en profiel van orale 
MIV toetsing op ’n positiewe manier uit te bou.  Die grondslag hiervoor sal gelê word deur te 
bewys dat die gebrek aan die behoefte van ’n bloedmonster in orale MIV toetsing ’n 
positiewe invloed op toetsing vir MIV/Vigs kan hê. 
 
In hierdie navorsingstuk word daar dan verder ’n spesifieke strategie voorgestel om orale 
MIV toetsing te bevorder, met die doel om meer mense te oortuig om vir MIV te toets.  
Hierdie strategie word basseer op die onderskeidende kenmerk van orale toetse – naamlik die 
afwesigheid van bloed – en behels die volgende:  Bewusmaking van orale MIV toetsing sal 
geskied deur ’n plakkaatveldtog te loods wat hierdie toetse as ’n meer 
“gebruikersvriendelike” alternatief tot ’n bloedtoets vir MIV sal bemark.  Op grondvlak sal 
die strategie uitgevoer word deur gebruik te maak van mobiele eenhede wat spesialiseer in 
orale MIV/Vigs toetsing.  Verder sal daar ook sekere riglyne voorgestel word vir die 
administrasie en gebruik van orale MIV toetse.   
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1 INTRODUCTION 
In December 1994, the US Food and Drug Administration (FDA)1 in the United States of 
America (USA) approved the OraSure® oral specimen collection device2 as a noninvasive 
Human Immunodeficiency Virus (HIV) antibody test.  At that stage, it was the first and only 
oral fluid HIV test to receive such endorsement by the FDA. 
 
(FDA (a), 2004 & Sheon, 1996) 
 
On March 26, 2004, the FDA accepted the OraQuick® Rapid HIV-1/2 Test2 for oral fluid.  
Currently, this is the first and only rapid HIV test to be approved in the USA by the FDA for 
use with oral fluid.  The FDA’s approval of the rapid test for use on oral fluid was limited to 
detection of antibodies to HIV-Type 1 (HIV-1).   
(Neergard, 2004 & Medical News Today, 2004) 
 
Then, on June 22, 2004, the FDA announced that it had also approved the OraQuick® Rapid 
HIV-1/2 Test for oral fluid to use in detecting HIV-Type 2 (HIV-2) antibodies in oral 
samples.   
(Neergard, 2004 & Medical News Today, 2004) 
 
Oral fluid tests and the rapid version thereof adds a whole new dimension to the voluntary 
counselling and testing (VCT) process, as no blood specimen – as opposed to the full blood 
or finger-prick rapid HIV test – needs to be taken to test for HIV anymore.   
 
The Orasure oral tests are the only FDA approved HIV oral tests in the USA.  Although the 
FDA approved the OraSure® oral specimen collection device in 1994 and the OraQuick®  
                                                 
1  The FDA is widely accepted as the benchmark for ensuring accurate and science-based information 
worldwide.  The FDA is responsible for protecting the public health in the USA by assuring the safety, efficacy, 
and security of human and veterinary drugs, biological products, medical devices, as well as food supply, 
cosmetics, and products that emit radiation.  The FDA has over 9,000 employees, located in 167 American 
cities.  Among its staff, the FDA has chemists, microbiologists, and other scientists, as well as investigators and 
inspectors who visit 16,000 facilities a year as part of their oversight of the businesses that the FDA regulates. 
(FDA (b), 2004) 
 
2  These oral fluid HIV tests are manufactured by OraSure Technologies, Inc., Bethlehem, Pennsylvania, USA. 
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Rapid HIV-1/2 Test for oral fluid in 2004 respectively, oral fluid tests still remain to be used 
in an official capacity in South Africa (SA) – no policy, guidelines or legislation regarding 
any aspect of oral fluid HIV testing currently exists in SA.  
 
Because decisions about testing are highly personal and individual, having a choice between 
conventional testing and rapid testing, would allow people to select the approach that suits 
them and their current circumstances best and thus would enhance their autonomy. 
(Elliot, 2000)   
 
Following from the above, oral fluid HIV testing expands the individual’s choice by offering 
a different kind of option, i.e. between the type of specimen for HIV testing.  In doing so, it 
enhances personal autonomy even further.  The individual now has a choice between a blood 
and a non-blood test to test for HIV.   
 
As there are no prescribed rules or regulations governing the use, application, promotion or 
distribution of oral tests in SA, this alternative HIV testing method is not well-known among 
the general South African public.  This raises the questions:  Do oral fluid HIV tests have any 
potential to be successfully used in SA?  Could it be labeled and marketed as a non-blood 
alternative test to test for HIV?  Could it help to increase voluntary testing for HIV in SA?   
 
It is important to note that it is not the aim of this study to argue that oral fluid testing should 
replace established blood specimen HIV tests like the full-blood Elisa test.  These tests must 
always be used for confirmatory purposes.   
 
The issue at hand is that the possible impact of oral fluid HIV tests still has to be fully 
realized in a South African scenario.  This research paper will focus specifically on the 
OraQuick® Rapid HIV-1/2 Test when trying to ascertain whether oral fluid HIV testing can 
play a significant and constructive role in the HIV testing set-up in SA. 
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2 RESEARCH OBJECTIVES 
The objectives of this research paper will be to: 
 
 determine if certain qualities of oral fluid HIV testing can be utilized to help increase 
the acceptance of testing for HIV in the public eye and convince more people to test.   
 establish whether the public opinion in SA among respondents who have been 
exposed to the OraQuick® Rapid HIV-1/2 Test for oral fluid are in favour of oral tests 
being administered by trained lay counsellors.   
 ultimately lay the foundation for the wider use of oral fluid tests in an official and 
structured capacity in SA (this paper will focus on the OraQuick® Rapid HIV-1/2 
Test for oral fluid).  
 
 
3 ORAL FLUID HIV TESTS:  A BRIEF GUIDE 
 
A THE ORASURE® ORAL SPECIMEN COLLECTION DEVICE 
As mentioned, the OraSure® oral specimen collection device was approved as a FDA 
noninvasive HIV antibody test in 1994.  This test extracts antibodies from the blood vessels 
in the mucous membranes of the mouth and IS NOT a saliva test.   
 
Like a blood test, OraSure® HIV-1 looks for antibodies to HIV, not the virus itself.  
OraSure® HIV-1 does not use saliva, but rather absorbs antibodies directly from the blood 
vessels in the mucous membranes.  The mucous membranes have a much higher amount of 
antibodies than does saliva.  
 
OraSure® HIV-1 uses a specially treated cotton fiber pad attached to a nylon stick which is 
placed between the lower cheek and gum and left for 2-5 minutes.  The OraSure® HIV-1 
collection pad draws IgG antibodies out of the tissues of the cheek and gum.  This sample, 
called oral mucosal transudate (OMT), contains far fewer contaminants than typically found 
in saliva.  If present, antibodies to the HIV-1 virus will be collected in this sample.  
 
The pad is then placed in the OraSure® HIV-1 transport vial.  This vial contains preservative 
which will keep the sample stable for up to 21 days at 2° C to 30° C.  The sample is then sent 
Stellenbosch University  http://scholar.sun.ac.za
  
 4
off to a qualified OraSure® HIV-1 testing laboratory for analysis using the Orasure® HIV-1 
testing algorithm.   
 
Testing of OraSure® HIV-1 oral fluid specimens is restricted to testing with the Oral Fluid 
Vironostika HIV-1 Microelisa System manufactured by Organon Teknika Corporation and 
the OraSure® HIV-1 Western Blot Kit (link to Western Blot). 
(Orasure, 2004) 
 
In the USA, the administration of this device is restricted to medical personnel who have 
been trained in the use of this device (Q. Pham,3 personal communication, 28 October 2004).  
 
 
B THE ORAQUICK® RAPID HIV-1/2 TEST FOR ORAL FLUID 
As discussed earlier, OraSure Technologies, Inc. announced that its OraQuick® Rapid HIV-
1/2 Antibody Test for oral fluid had received approval from the FDA for use in detecting 
antibodies to both HIV-1 (March 2004) and HIV-2 (June 2004) in oral fluid.   
 
Also in June 2004, OraSure announced that the OraQuick® Rapid HIV-1/2 Test for oral fluid 
had received a CLIA (Clinical Laboratory Improvements Amendments of 1988) waiver, 
which will allow the test to be used by more than 180,000 sites in the USA, including more 
health care settings, such as doctors' offices, outreach clinics, community-based organizations 
and some mobile labs that can offer testing in high-risk areas.  
 
Originally, the use of the OraQuick® Rapid HIV-1/2 Test to detect antibodies to HIV in oral 
fluid had been limited to certified laboratories (high and moderate complexity laboratories 
under CLIA).  However, as a result of the waiver from the requirements of CLIA, all clinical 
laboratories certified through CLIA (high, moderate, and waived) can now use this test.   
 
Because the OraQuick® Rapid HIV-1/2 Test is simple and accurate, the FDA approved it as 
a waived test.  Waived tests are determined to be easy to use and have little risk of an 
incorrect result.  In the USA, non-clinical testing sites that plan to provide the OraQuick test 
                                                 
3  Quoc Pham is the regional director for OraSure Technologies, Inc. for Africa and Asia. 
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must either apply for their own CLIA Certificate of Waiver or establish an agreement to work 
under the CLIA Certificate of an existing laboratory.  Any agency that has a CLIA Certificate 
of Waiver and is performing the OraQuick® Rapid HIV-1/2 Test, is considered a clinical 
laboratory.  
 
Orasure unveiled the OraQuick® Rapid HIV-1/2 Antibody Test for oral fluid under a new 
name, the OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test, on October 21, 2004 at the 
United States Conference on Acquired Immunodeficiency Syndrome or AIDS, held at the 
Philadelphia Marriott Hotel in Philadelphia, Pennsylvania.   
 
Like the OraSure® HIV-1 Oral Specimen Collection Device, this test extracts antibodies 
from the blood vessels in the mucous membranes in the mouth and IS NOT a saliva test.  
Although the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test has received a CLIA 
waiver, it is restricted for use in the USA by trained medical persons (Q. Pham, personal 
communication, 28 October 2004). 
 
To perform the test, the person being tested for HIV gently swabs completely around 
the outer gums, both upper and lower, one time around.  The tester then takes the device 
and inserts it into a vial containing a developer solution.  In as little as 20 minutes, the test 
device will indicate if HIV antibodies are present in the solution by displaying two 
reddish-purple lines in a small window in the device. 
(Orasure, 2004 & Centers for Disease Control and Prevention or CDC (a), 2004) 
 
 
C ORAL FLUID TESTING: A SOUTH AFRICAN PERSPECTIVE 
The Human Tissue Act, Act 65 of 1983, only allows health workers to administer HIV tests 
that require a blood sample (Medical Research Council or MRC, 2001).  This means that only 
certified phlebotomists are allowed to conduct blood rapid and full blood tests.   
 
General discussions of certain HIV tests are featured in, for example, the Presidential AIDS 
Advisory Report (Department of Health (a), 2001); and papers like HIV/AIDS Policy 
Guideline: Rapid HIV Testing (Department of Health (b), 2000).  In no official documents, 
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however, is mention made of oral fluid HIV testing or tests and no laws exist regarding the 
administration of oral fluid tests in SA.  But this does not mean that oral fluid tests are not 
being used in SA.   
 
The OraSure® oral specimen collection device was used in the first Nelson Mandela/HSRC 
Study of AIDS (Human Sciences Research Council or HSRC, 2002).   
 
OraSure has successfully completed its clinical trial for the OraQuick® Rapid HIV-1/2 Test 
with the National Institute for Virology (NIV) in SA.  The NIV functions as the national 
resource centre for viral diseases in SA, and is a public health institute within the Department 
of Health providing comprehensive medical virological diagnostic services.  This clinical trial 
is a requirement for companies to participate in the public tender business in SA. 
(Business Wire, 2001) 
 
The OraQuick® Rapid HIV-1/2 Test for oral fluid is currently being used in governmental 
VCT sites in Kwazulu-Natal (KZN).  As a result of oral fluid rapid testing resources at these 
sites being fully stretched, medically trained personnel (for example nurses) have had to turn 
to lay counsellors to help conduct oral fluid rapid HIV testing in order to meet the demand  
(J. Hills,4 personal communication, 31 August 2004). 
 
 
                                                 
4  Jackie Hills is associated with UCB Pharma – the company which is the sole distributor of the OraQuick® 
Rapid HIV-1/2 Test for oral fluid in SA. 
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4 RESEARCH PROBLEM 
The aim of this research paper is to determine if individuals can be motivated to test for HIV 
by using the oral fluid test’s distinct quality - of having no blood barrier to overcome - as the 
point of departure and consequently the selling point. 
 
In essence, the research problem to be discussed and analyzed is: 
 
Can the lack of the need for a blood specimen in oral fluid HIV testing positively 
influence testing for HIV? 
 
5 WHY USE THE BLOOD BARRIER TO INCREASE TESTING? 
 
 The lack of the need for a blood specimen is the major contributing factor to the 
noninvasive nature of the oral testing.  This characteristic of oral testing can 
facilitate in changing the view that people might have of HIV testing as being 
uncomfortable as a result of having to give a blood sample, thereby positively 
influencing testing for HIV:  
 
The New York State Department of Health (NYSDOH) AIDS Institute’s Anonymous 
HIV Counselling and Testing Program (ACT) in the USA conducted an 11-week oral 
fluid testing implementation and preference pilot study in June of 1997.  The ACT 
programme provided services in both the community and state correctional services.   
 
During the study period, all clients at these sites were offered a choice of 
venipuncture or oral fluid testing.  At the conclusion of the pre-test session, clients 
participating were asked to complete a survey.  This survey collected information as 
to the reasons clients chose a particular testing method.   
 
Stellenbosch University  http://scholar.sun.ac.za
  
 8
Thirty-seven percent (37%) of programme clients tested in the community and who 
selected oral fluid testing, indicated that the most important reason for their selection 
was that “this method seemed easier than blood testing”, while 53% of inmates who 
selected oral fluid testing also cited this reason.   
(Berberian et al, 1998) 
 
Since 1987, HIV testing and counselling has been a cornerstone of HIV prevention 
efforts in the state of Michigan, USA.  Testing and counselling are provided in each 
of the state’s local public health agencies as well as through 51 community-based and 
non-governmental agencies in the country.   
 
Ongoing quality assurance and evaluation activities conducted by the Michigan 
Department of Community Health (MDCH) included assessment of barriers to access 
and appropriate use of prevention strategies.  One of the barriers to the use of 
counselling and testing services that was identified was related to the method of 
specimen collection, i.e. the taking of a blood specimen.  This included client 
difficulty with blood-draw and in instances where client venous was compromised it 
proved inappropriate. 
 
The strategy used to address this barrier, was the use of oral fluid for HIV testing.  
Beginning in March 1997, the MDCH made oral fluid collection devices available to 
all community-based organizations.  Oral fluid based testing had been integrated with 
ongoing out reach and health education activities.  The goal in mind: To overcome the 
barrier to the method of specimen collection and increase access to and appropriate 
utilization of counselling and testing services in at-risk populations. 
 
A year after statewide implementation of oral fluid testing, it was concluded that the 
MDCH had been largely successful in achieving the abovementioned goal. 
(Randall, 1998) 
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According to Vargo (2004), the OraSure® oral specimen collection device along with 
social network recruitment, were used to help increase testing for HIV in a minority 
community in Springfield, Massachusetts, USA. 
 
Over an 11-month period, the number of test takers at the intervention site increased 
by 71.7%.  At a comparison site, testing remained stable.  The use of a social network 
recruitment strategy in combination with the noninvasive OraSure® oral specimen 
collection device showed promise in increasing testing and in targeting populations. 
 
 
 People not testing for HIV are scared of the needles involved.  The absence of the 
“fear factor” of blood and needles in oral testing can be used to persuade those 
who are scared of blood and needles to test for HIV: 
 
The American state of Maryland sought to increase access and utilization of HIV 
testing and counseling services (CTS) with an oral fluid test demonstration project in 
1997-98.  A number of clients who agreed to oral testing indicated that they would not 
have been tested if the oral option was unavailable. 
 
Participants in the oral fluid testing demonstration project completed a client survey 
assessing responses to the test (n = 1432).  Of these clients, 21.1% agreed or strongly 
agreed that they would not have been tested if the oral option had not been available 
(i.e. blood-test avoiders).   
(Bauserman et al, 1999) 
 
Also in the state of Maryland, the Orasure® Demonstration Project introduced oral 
HIV testing for incarcerated persons at 32 counselling and testing sites between 
September 1997 and April 1998.  Persons in the local detention and juvenile justice 
facilities chose oral and blood testing and reported reactions to the oral test.   
 
Reactions to the oral testing were most favourable.  Importantly, 18% of men and 
16% of women indicated that they had putt of or refused testing in the past owing to 
Stellenbosch University  http://scholar.sun.ac.za
  
 10
the fear of needles, and 22% of men and 15% of women said that they would not have 
been tested without the oral option. 
(Bauserman et al, 2001) 
 
Research was launched to provide an overview of the use of Orasure® testing devices 
for HIV testing via a mobile unit as an innovative strategy for delivery to expand 
treatment in a resource limited community in Miami, Florida, USA. 
 
From the time period of May 2001 to May 2002, 1,198 individuals were tested.  It 
was found that Orasure® testing devices, due to the lack of use of blood in the testing 
environment of the mobile unit, is a viable approach and an innovative mechanism for 
HIV testing.  The mobile unit, combined with the testing approach, eliminated the 
need to draw blood and reduced the fear level of patients.   
(Rose et al, 2003) 
 
Burger (2003) reported that an international oil company in SA decided to offer 
employees in the company the opportunity to get to know their own HIV status 
through a Know Your Status campaign launched in the beginning of 2003.  A total of 
776 people came forward for testing – 47% of the total number of permanent staff 
members and contractors.  Because of the low testing percentage, an audit was done 
to determine the reasons for the low testing uptake.   
 
From the audit, it was determined that one of the issues that prevented some people 
from testing, was the exclusive full-blood test using needles.  Forty percent (40%) of 
respondents who did not test, indicated that the use of needles made them decide not 
to test.  Some respondents who did test, indicated a preference for an alternative HIV 
test to a full-blood test using needles, for example a rapid or an oral HIV test (17%). 
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 Oral fluid HIV tests are safe to use and administer.  Oral fluid testing removes 
possible safety concerns of HIV tests involving a blood specimen that could put 
off some individuals from testing or result in needle stick injuries:  
 
Health care workers (HCWs) face a much lower risk of exposure to infectious 
diseases from oral fluid than from blood.  Specimens can be readily collected from 
any individual, without risk of transmission. 
(CDC (a), 2004) 
 
Following from the discussion of Randall (1998) earlier in this paper, the MDCH 
assessed that one of the barriers to the use of counselling and testing services that was 
identified was related to the method of specimen collection, i.e. the taking of a blood 
specimen.  Another dimension of the blood taking procedure that caused 
complications was the safety of the provider that was often jeopardized by following 
this procedure, i.e. through needle stick injuries.  As mentioned, the MDCH had been 
mainly successful in eradicating this problem by implementing the use of oral fluid 
testing. 
 
According to Rele et al (2002), HCWs are at a risk of occupational acquisition of HIV 
infection, primarily due to accidental exposure to infected blood and body fluids.  At 
the public hospital in question , over a period of one year (June 2000 - 2001) a total 
number of 38 self reported incidences of needle stick injuries and other exposures to 
patient’s blood and body fluids were reported by HCWs.   
 
A greater incidence of occupational exposure was seen in surgery residents as 
compared to medicine residents.  It was concluded that needle stick injuries present 
the single greatest risk to medical personnel and the importance of increased 
awareness and training in universal safety precautions, for prevention of nosocomial 
infection.  
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 Oral fluid HIV tests are accurate and reliable.  The fact that this test is precise 
and dependable without having to give a blood sample can be influential in 
convincing individuals to test for HIV: 
 
Tests conducted using the OraSure® HIV-1 Oral Specimen Collection Device, 
indicated that HIV-1 antibody testing of oral fluid is highly accurate.  In the entire 
study population of 3570 subjects, the result obtained was incorrect for only one 
individual.  In 3569 (>99.9%) of 3570 subjects, either the correct result was obtained 
with the initial oral fluid sample or appropriate follow-up testing would be triggered.   
 
By following the Orasure® HIV-1 testing algorithm, 3558 of 3570 subjects received 
the correct HIV-1 antibody result from a single oral fluid sample.  In 11 of the 12 
remaining subjects, the Western blot was indeterminate; for these 11, the algorithm 
would lead to appropriate follow-up testing.   
(Gallo et al, 1997) 
 
Data from clinical trails submitted by OraSure Technologies, Inc. and reviewed by the 
FDA, showed that in limited clinical studies the OraQuick® Rapid HIV-1/2 Antibody 
Test provided a highly accurate HIV test result, correctly identifying at least 99.3% of 
specimens from HIV-infected persons and at least 99.8% of specimens from 
uninfected persons. 
(CDC (a), 2004) 
 
The launch of the OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test followed 
the successful completion of a previously announced assessment conducted by 
OraSure Technologies, Inc. regarding a subset of data from an isolated clinical trial of 
the new oral fluid test.  As part of the assessment, OraSure Technologies, Inc. 
executed a study that reflected the use of the test in the field, in which over 12,000 
test readings were reviewed.   
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The results from that study, in addition to data analyzed from several independent 
studies involving over 7,000 oral fluid samples, clearly indicate that the test is 
operating within its specifications. 
(Orasure, 2004)  
 
In KZN, SA, there is a large rural and urban population that constantly requires access 
to various formats of HIV testing.  York et al (2002) reports that an investigation was 
launched in 2002 using four commercial assays, either oral, urine, whole blood or 
serum as diagnostic sample for the diagnosis of HIV.  
 
One of the objectives was to assess the performance of the OraQuick® Rapid HIV-1/2 
Test for oral fluid.  An oral sample was collected from each of 500 pre-counselled 
consenting antenatal attendees at King Edward the VIIIth hospital.  The oral test was  
performed at the clinic.  The results were as follows: 
 
o Sensitivity5:  98.6%  
o Specificity6:  98.6% 
 
The rapid results compared favourably with the more costly and technologically 
demanding full blood tests.  Oral fluid was also comparably sensitive and specific as 
diagnostic sample.  The oral  assay formats performed well on the local population 
strain which is essentially infected with HIV clade C. 
 
 
                                                 
5  The ability of the oral fluid test to detect HIV positive results. 
 
6  The ability of the oral fluid test to detect HIV negative results. 
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 If non-medically trained individuals are allowed to administer the oral testing 
process in an officially sanctioned capacity - based on the premise that no 
specialist blood taking procedure is involved in this relatively easy process - the 
number of administrators conducting testing will increase.  This could positively 
influence the testing infrastructure for HIV (especially in remote, resource 
limited areas): 
 
In research conducted using the OraSure® HIV-1 Oral Specimen Collection Device, 
undertaken through community-based AIDS outreach programmes in certain 
American states, both medical and nonmedical personnel were trained in the use of 
the oral specimen collection device and in HIV education, prevention, and partner 
notification.   
 
Locations for the collection of specimens included such diverse settings as street 
corners, halfway houses, correctional facilities, gay bathhouses, shopping malls, 
supermarkets, and schools and universities. Collection was performed both 
individually and in groups. 
 
Over a period of three months, 2934 specimens were collected from economically and 
ethnically diverse study populations.  It was found that oral HIV testing may be 
performed in any setting by minimally trained medical and non medical personnel.  
The potential to administer it in any setting appears to overcome certain logistical 
barriers to HIV testing, greatly expanding the reach of traditional counselling and 
testing programmes. 
(Judson et al, 1996) 
 
In a study on how to address the logistical complexity for HIV surveillance in 
difficult-to-access areas, Respess et al (2001) concluded that oral fluids could be 
collected in a variety of field settings, including non-clinical settings.  It was also 
found that oral fluid collection may be more acceptable to hard-to-reach populations 
than specimen collection requiring venipuncture or finger stick. 
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In research done in Minneapolis, Minnesota, USA, HIV prevention counsellors 
received additional training to do OraQuick® Rapid HIV-1/2 Test for oral fluid 
testing using oral fluid.  They went to community-based organizations such as 
chemical dependency programmes, homeless shelters, etc.  The team did onsite pre-
test counselling, testing, and post-test counselling (including clients with reactive 
tests). 
 
The study showed that rapid HIV testing enabled a high percentage of clients to learn 
test results.  HIV prevention counsellors from non-medical backgrounds were able to 
achieve proficiency in OraQuick® testing.    
(Keenan et al, 2004) 
 
 
6 RESEARCH METHODOLOGY 
A RESEARCH DESIGN 
An attitude survey7 was done among the 350 employees at the Santam Head Office in 
Bellville, South Africa, during October/November 2004 to determine if the lack of the need 
for a blood specimen in oral fluid HIV testing could play a role in promoting voluntary HIV 
testing. 
 
Employees from Santam were chosen as population for this survey because they had been 
exposed to the workings of the OraQuick® Rapid HIV-1/2 Test for oral fluid during a 
HIV/AIDS intervention launched in September 2004.  Here they gained first hand knowledge 
of this oral fluid test - by learning about it during compulsory HIV/AIDS awareness training 
and pre-test counselling sessions.  They also had the opportunity to voluntary test for HIV by 
using the OraQuick® Rapid HIV-1/2 Test for oral fluid.  Administration of the tests was 
conducted by lay counsellors. 
 
The survey method is a widely used descriptive research technique.  According to 
Christensen (2001), a survey can be defined as a field study in which an interview technique 
                                                 
7  See Addendum A for the survey questions.  The results and discussion of the survey follow later in this paper. 
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is used to gather data on a given state of affairs in a representative sample of the population.  
Kerlinger (1992) states that surveys are appropriate for gathering data regarding opinions and 
attitudes on the one hand, and behaviour on the other.  According to Shiffman and Kanuk 
(1994) the survey is an accepted method of measuring both attitudes and behaviours.   
 
The descriptive research technique provides a description or a picture of a particular situation, 
and tries to describe the relationship that exists between variables.  In this case scenario, 
neither random assignment nor experimental manipulation of the variables are possible, 
therefore an descriptive research approach, and more specifically an ex post facto research 
design, will be used in this study.  This is because the variables are not under the 
experimenter’s control and are not subject to direct manipulation but must be chosen after the 
fact. 
(Christensen, 2001) 
 
The weaknesses and limitations of the particular design were taken into consideration during 
the interpretation of the results. These include low response frequency and incomplete 
response information (Kerlinger, 1992).  Other possible disadvantages of a survey include 
sampling error, time required, and constraints in the length of the survey.  
 
(Christensen, 2001 & Theron, 2001) 
 
 
B SAMPLING 
Because the survey is optional to complete, each employee in the sample of size n= 350 had 
the same probability of being part of the survey.  All responses were gathered over a two 
week period.   
 
C DATA COLLECTION 
Respondents were notified via the Santam intranet of the survey.  The survey questionnaire 
was distributed by the secretaries of Santam’s various departments.  Employees of the various 
departments were randomly asked to complete it. 
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At the beginning of the survey, respondents were assured that the survey was voluntary, 
anonymous and confidential.  If they chose to proceed, they were asked to indicate their 
gender and specific age group. 
 
The first survey question tried to ascertain how respondents perceived the use of the 
OraQuick® Rapid HIV-1/2 Test during the recent intervention.8  In doing this, they were 
assigned to one of three groups:  
 
 Those who perceived the use of the OraQuick® Rapid HIV-1/2 Test to have been a 
success 
 Those who perceived the use of the OraQuick® Rapid HIV-1/2 Test as being 
unsuccessful 
 Those who were undecided about the issue 
 
For Question 2, the following issue was under discussion:  If you had to make a choice, 
would you prefer to test for HIV by giving a blood specimen, an oral specimen or doesn’t it 
matter which specimen you have to give?9   
 
In doing so, respondents were assigned to one of three groups:  
 
 Those who prefer to test for HIV by giving a blood specimen 
 Those who prefer to test for HIV by giving an oral specimen 
 Those who feel indifferent toward the issue 
 
Christensen ( 2001) defines open-ended questions as questions that enable respondents to 
answer in any way they please; and closed-ended questions as questions that require 
respondents to choose from a limited number of predetermined responses.  These type of 
questions were not applicable for and could not be used to test attitudes regarding the stated 
                                                 
8  Refer to Question 1 in the survey. 
 
9  Refer to Question 2 in the survey. 
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research problem.  Therefore, the rest of the survey was made up of questions10 in the form of 
attitude statements and completed via the survey by using a Likert scale format. 
 
The reasons for this were that the survey could only be done after the whole testing 
intervention at Santam was completed, as well as the fact that Santam employees tested for 
HIV using a barcode system as identification, which guaranteed anonymity and 
confidentiality.  If the survey questions were asked using open-ended or closed-ended 
questions, it would have meant that employees who tested had to first be identified in order to 
complete the questionnaire.  This was impossible to do, as testing was done anonymously and 
such actions would have jeopardized confidentiality in any case. 
 
As a result, not all employees that completed the survey, tested.  In the chosen population 
however, there was a 95% testing take-up.  Taking into account the high testing take-up, as 
well as the fact that all Santam employees learned about oral tests during compulsory 
HIV/AIDS awareness training and pre-test counselling sessions before the testing 
intervention, the following deductions are made:   
 
 the majority of respondents who completed the survey did test, and 
 the small percentage who did not test but completed the survey, were taught about the 
workings of the oral test during training sessions. 
 
Therefore, the assumption is made that all respondents were able to form a learned opinion of 
these tests, irrespective of whether they tested or not.  Santam employee’ response and 
opinion were thus considered as pivotal to providing an answer to the stated research 
problem. 
 
For Questions 3 – 8, a Likert scale was used.  This scale measures the extent to which a 
person agrees or disagrees with a question (Kirakowski, 2004).  The Likert technique 
presents a set of attitude statements.  Subjects were asked to express agreement or 
disagreement on a five-point scale. 
 
                                                 
10  Refer to Questions 3 - 8 in the survey. 
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Each degree of agreement is given a numerical value from one to five.  Consequently, a total 
numerical value can be calculated from all the responses.  Each respondent was asked to rate 
each question in the survey (i.e. item on the Likert scale).  These items were rated on a 1-to-5 
Agree - Disagree response scale where: 
 
 1 = strongly agree 
 2 = agree 
 3 = neither agree nor disagree 
 4 = disagree 
 5 = strongly disagree 
 
For the questions under discussion, respondents were asked to indicate the extent of their 
agreement or disagreement with a particular statement: 
 
 Questions 3 – 5 dealt with psychological barriers to HIV testing. 
 Questions 6 – 7 dealt with the scientific relevance of HIV testing. 
 Question 8 dealt with logistical aspects of HIV testing.   
 
For the interpretation of the Likert scale results for Questions 3 - 8, the answers of the three 
groups mentioned in Question 2 of the survey will be used, i.e. 
 
 those who prefer to test for HIV by giving a blood specimen (Group 1); 
 those who prefer to test for HIV by giving an oral specimen (Group 2); and 
 those who feel indifferent towards the issue (Group 3). 
 
The answers for Questions 3 – 8 in the survey will be examined and analyzed by: 
 
 comparing the mean responses of the three groups for each of the questions 
respectively; 
 using analysis of variance (ANOVA) to determine significant differences in the mean 
responses of the three groups at a 5% significance level (p<0.05); and 
 discussing the relevance of these differences/lack of these differences. 
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7 RESULTS  
A total of 145 responses were gathered during the two week period.  Of these, 142 were fully 
completed.  The discussion of the demographics and results of the survey questions11 are 
summarized as follows: 
 
 
7.1 SURVEY DEMOGRAPHIC BACKGROUND 
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FIGURE 7.1 
Figure describing the gender distribution of the employees who completed the attitude survey.  
 
 In the survey, 50% of respondents were male and 43% were female.  Seven percent (7%) 
of the respondents did not indicate their gender. 
 
 
                                                 
11  See Addendum A for the survey questions. 
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FIGURE 7.2 
Figure describing the age group distribution of the employees who completed the attitude 
survey.  
 
 In terms of age groups, 21.13% of employees were younger than 30 years; 47.89% were 
between 30 and 40 years and 30.99% were older than 40 years.   
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7.2 DISCUSSION OF SURVEY QUESTIONS 1 & 2 
 
 
Yes No Undecided
Question 1
0
20
40
60
80
100
120
140
n 
of
 re
sp
on
de
nt
s
 
FIGURE 7.3 
Figure describing the perceived success rate of the use of the OraQuick® Rapid HIV-1/2 Test in 
the VCT process. 
 
 From Figure 7.3 it can be seen that the use of the OraQuick® Rapid HIV-1/2 Test was 
perceived as a big success.  More than 85% of respondents thought that the use of oral 
tests in the VCT process was a successful venture. 
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FIGURE 7.4 
Figure describing employee preference for a specific HIV test. 
 
 More than 50% of respondents indicated that they would prefer oral fluid tests when 
testing for HIV.  Less than 10% of employees preferred a blood test to test for HIV.  
Almost 40% of respondents indicated that they felt indifferent towards the issue.   
 
 
7.3 DISCUSSION OF THE LIKERT SCALE SURVEY QUESTIONS 3 - 8 
As discussed earlier, the answers of the three groups mentioned in Question 2 of the survey 
(Figure 7.4 above), i.e. respondents who 
 
 prefer to test for HIV by giving a blood specimen (Group 1); 
 prefer to test for HIV by giving an oral specimen  (Group 2); and 
 feel indifferent towards the issue (Group 3) 
 
were compared with results of Questions 3 – 8 in the survey. 
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7.3.1  DISCUSSION OF THE LIKERT SCALE SURVEY - QUESTION 3 
 
TABLE 7.1 
Table giving an overview of the descriptive statistics for the three groups with respect to survey 
Question 3. 
 
Cell No.
Question 2 Question 3
Mean
Question 3
Std.Err.
N
1
2
3
Group 1 2.21 0.15 14
Group 2 1.46 0.07 72
Group 3 1.75 0.08 56  
 
 
FIGURE 7.5 
Graph showing the average response for Question 3 per group. 
 
 Ascertaining from Table 7.1 and Figure 7.5, all the groups either agreed or strongly 
agreed that the noninvasive nature of oral fluid testing could serve as motivation for more 
individuals to test for HIV.  Group 1 had the highest average, with Group 2 the lowest 
(i.e. agreeing most strongly). 
F(2, 139)=11.395, p=<0.01 Kruskal-Wallis p<0.01
Vertical bars denote 0.95 confidence intervals
Group 1 Group 2 Group 3
Question 2
1.2 
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TABLE 7.2 
Table showing the post hoc comparisons for the three groups with respect to survey Question 3. 
 
Bonferroni test; variable Question 3 
Cell No.
Question 2 {1}
2.2143
{2}
1.4583
{3}
1.7500
1
2
3
Group 1 p < 0.01 0.02
Group 2 p < 0.01 0.02
Group 3 0.02 0.02  
 
 From Table 7.2 it can be seen that there was a statistically significant difference (p<0.05) 
between the averages of all three groups regarding Question 3.  It is important to note that 
all three groups, to some extent, agreed on the issue in question. 
 
 
7.3.2  DISCUSSION OF THE LIKERT SCALE SURVEY - QUESTION 4 
 
TABLE 7.3 
Table giving an overview of the descriptive statistics for the three groups with respect to survey 
Question 4. 
 
Cell No.
Question 2 Question 4
Mean
Question 4
Std.Err.
N
1
2
3
Group 1 2.29 0.17 14
Group 2 1.43 0.08 72
Group 3 1.66 0.09 56  
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FIGURE 7.6 
Graph showing the average response for Question 4 per group. 
 
 From Table 7.3 and Figure 7.6, on average, all the groups either agreed or strongly agreed 
that the lack of fear of needles and blood in oral fluid HIV testing could be instrumental 
in motivating more individuals to take the test.  Group 1 again had the highest average 
with Group 2 the lowest. 
 
TABLE 7.4 
Table showing the post hoc comparisons for the three groups with respect to survey Question 4. 
 
Bonferroni test; variable Question 4 
Cell No.
Question 2 {1}
2.2857
{2}
1.4306
{3}
1.6607
1
2
3
Group 1 p < 0.01 p < 0.01
Group 2 p < 0.01 0.14
Group 3 p < 0.01 0.14  
 
 From Table 7.4 it is observed that there was no statistically significant difference 
(p=0.14) between the averages of Group 2 and Group 3.  There was a highly significant 
statistical difference between Group 1 on the one hand and Group 2 and Group 3 
respectively on the other hand (p<0.01).  What is relevant, is that all three groups agreed 
on the issue under discussion. 
F(2, 139)=10.781, p=<0.01 Kruskal-Wallis p<0.01
Vertical bars denote 0.95 confidence intervals
Group 1 Group 2 Group 3
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7.3.3  DISCUSSION OF THE LIKERT SCALE SURVEY - QUESTION 5 
 
TABLE 7.5 
Table giving an overview of the descriptive statistics for the three groups with respect to survey 
Question 5. 
 
Cell No.
Question 2 Question 5
Mean
Question 5
Std.Err.
N
1
2
3
Group 1 2.50 0.18 14
Group 2 1.53 0.08 72
Group 3 1.84 0.09 56  
 
 
 
FIGURE 7.7 
Graph showing the average response for Question 5 per group. 
 
 Deducing from the mean answers to Question 5, the three groups agreed or strongly 
agreed that the absence of a transmission risk through oral testing could be a motivating 
factor to test for HIV.  Again, the trend of Group 2 having the highest average and Group 
1 the lowest is noted. 
 
F(2, 139)=12.698, p=<0.01 Kruskal-Wallis p<0.01
Vertical bars denote 0.95 confidence intervals
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TABLE 7.6 
Table showing the post hoc comparisons for the three groups with respect to survey Question 5. 
 
Bonferroni test; variable Question 5 
Cell No.
Question 2 {1}
2.5000
{2}
1.5278
{3}
1.8393
1
2
3
Group 1 p < 0.01 p < 0.01
Group 2 p < 0.01 0.03
Group 3 p < 0.01 0.03  
 
 There was a statistically significant difference (p<0.05) between the average answers of 
all the groups regarding Question 5.  It is imperative to bear in mind that all three groups 
displaying a statistically significant difference in terms of answering this question still 
agreed – but to different degrees - that safety issues could play a part in motivation for 
HIV testing. 
 
7.3.4  DISCUSSION OF THE LIKERT SCALE SURVEY - QUESTION 6 
 
TABLE 7.7 
Table giving an overview of the descriptive statistics for the three groups with respect to survey 
Question 6. 
 
Cell No.
Question 2 Question 6
Mean
Question 6
Std.Err.
N
1
2
3
Group 1 3.07 0.21 14
Group 2 1.79 0.09 72
Group 3 2.13 0.11 56  
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FIGURE 7.8 
Graph showing the average response for Question 6 per group. 
 
 Table 7.7 and Figure 7.8 suggest that all three groups had a different viewpoint pertaining 
to whether the proven accuracy levels of oral tests to test for HIV without the need for a 
blood sample could play a part in motivation to test for HIV.  On average, respondents in 
Group 1 felt indifferent towards the issue; Group 2 respondents tended to strongly agree 
that the proven accuracy levels of oral tests to test for HIV without the need for a blood 
sample could influence motivation to test; while Group 3 respondents generally agreed it 
could play a part.   
 
As observed with previous questions, the trend of Group 1 having the highest average and 
Group 2 the lowest (i.e. agreeing most strongly) is again prominent. 
 
 
F(2, 139)=15.771, p=<0.01 Kruskal-Wallis p<0.01
Vertical bars denote 0.95 confidence intervals
Group 1 Group 2 Group 3
Question 2
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TABLE 7.8 
Table showing the post hoc comparisons for the three groups with respect to survey Question 6. 
 
Bonferroni test; variable Question 6
Cell No.
Question 2 {1}
3.0714
{2}
1.7917
{3}
2.1250
1
2
3
Group 1 p < 0.01 p < 0.01
Group 2 p < 0.01 0.06
Group 3 p < 0.01 0.06  
 
 From Table 7.8 it can be seen that, like Question 4, there was a highly statistically 
significant difference (p<0.01) between the answers of Group 1 on the one hand and 
Group 2 and Group 3 respectively on the other hand.  There was no statistical difference 
(p=0.06) between Group 2 and Group 3.   
 
Deduced from these research results, individuals in the population who prefer blood HIV 
tests, are of the opinion that the promotion of the accuracy level of oral tests to test for 
HIV will not play an important part in convincing individuals to test. 
 
 
7.3.5  DISCUSSION OF THE LIKERT SCALE SURVEY - QUESTION 7 
 
TABLE 7.9 
Table giving an overview of the descriptive statistics for the three groups with respect to survey 
Question 7. 
 
Cell No.
Question 2 Question 7
Mean
Question 7
Std.Err.
N
1
2
3
Group 1 2.86 0.22 14
Group 2 1.79 0.10 72
Group 3 2.13 0.11 56  
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FIGURE 7.9 
Graph showing the average response for Question 7 per group. 
 
 The average scores in Table 7.9 and Figure 7.9 suggest that respondents from Group 2 
and Group 3 agreed or strongly agreed that the proven reliability of oral fluid HIV tests to 
test for HIV without the need for a blood sample could play a part in motivation to test.  
Group 1 respondents tended to be more indifferent toward the issue.  As in the case with 
the averages for Question 3, Question 4, Question 5 and Question 6, Group 2 has the 
highest average and Group 1 the lowest. 
 
TABLE 7.10 
Table showing the post hoc comparisons for the three groups with respect to survey Question 7. 
 
Bonferroni test; variable Question 7 
Cell No.
Question 2 {1}
2.8571
{2}
1.7917
{3}
2.1250
1
2
3
Group 1 p < 0.01 0.01
Group 2 p < 0.01 0.08
Group 3 0.01 0.08  
 
 Like the results for Question 4 and Question 6, the same tendency can be seen in Table 
7.10 for Question 7.  There was a highly statistical significant difference (p<0.01) 
between the answers of Group 1 in the one corner and Group 2 and Group 3 respectively 
F(2, 139)=10.291, p=<0.01 Kruskal-Wallis p<0.01
Vertical bars denote 0.95 confidence intervals
Group 1 Group 2 Group 3
Question 2
1.4 
1.6 
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2.6 
2.8 
3.0 
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3.6 
3.8 
Question 7
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in the other corner.  Like the trend in Question 6, Group 1 and Group 2 did not show a 
statistical difference (p=0.08) in their responses.   
 
Judging from these findings, individuals in the population who prefer blood HIV tests, are 
of the opinion that the promotion of the reliability of oral fluid HIV tests to test for HIV 
would not play an important part in convincing individuals to test. 
 
 
7.3.6  DISCUSSION OF THE LIKERT SCALE SURVEY - QUESTION 8 
 
TABLE 7.11 
Table giving an overview of the descriptive statistics for the three groups with respect to survey 
Question 8. 
 
Cell No.
Question 2 Question 8
Mean
Question 8
Std.Err.
N
1
2
3
Group 1 2.43 0.21 14
Group 2 1.81 0.09 72
Group 3 2.11 0.11 56  
 
 F(2, 139)=4.6629, p=0.01 Kruskal-Wallis p<0.01
Vertical bars denote 0.95 confidence intervals
Group 1 Group 2 Group 3
Question 2
1.4 
1.6 
1.8 
2.0 
2.2 
2.4 
2.6 
2.8 
3.0 
 
FIGURE 7.10 
Graph showing the average response for Question 8 per group. 
 
 The mean answers to Question 8 indicate that all three groups either agreed or strongly 
Question 8
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agreed that trained lay counsellors should be allowed to administer oral rapid testing.  The 
same trend as previously discussed pertaining to Group 1 and Group 2, continues. 
 
 
TABLE 7.12 
Table showing the post hoc comparisons for the three groups with respect to survey Question 8. 
 
Bonferroni test; variable Question 8 
Cell No.
Question 2 {1}
2.4286
{2}
1.8056
{3}
2.1071
1
2
3
Group 1 0.02 0.54
Group 2 0.02 0.11
Group 3 0.54 0.11  
 
 Table 7.12 suggests that there was a statistically significant difference (p=0.02) between 
the answers of Group 1 and Group 2.  No statistically significant difference was found 
between the answers of Group 1 and 3 (p=0.54) and Group 2 and 3 (p=0.11) respectively.  
It is important to note that to a certain level, all three groups agreed on the issue in 
question. 
 
 
7.4 RESULTS SUMMARY OF LIKERT SCALE SURVEY QUESTIONS 
In summary, two trends have been identified: 
 
 In all the questions, when comparing the average responses of the three groups, Group 2 
had the highest average, Group 1 the lowest and Group 3 fell somewhere in between. 
 
 In Question 4, Question 6 and Question 7, there was a statistically significant difference 
(p<0.05) between the averages of Group 1 on the one hand and Group 2 Group 3 on the 
other hand, with no significant difference detected between the mean responses for Group 
2 and Group 3. 
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8 RECOMMENDATIONS 
The results of this research paper indicate that there are a strong preference for oral fluid 
testing and that a campaign highlighting the various advantages that oral fluid testing offers 
above conventional HIV testing because no blood specimen is required, could boost testing 
averages.  Therefore, the following recommendation is made: 
 
 Devise a strategy to promote the use of the OraQuick® Rapid HIV-1/2 Test for 
oral fluid. 
 
A poster campaign12 is suggested as strategy to promote the use of the Oraquick® 
Rapid HIV-1/2 Test for oral fluid.  Posters with pictures and slogans could be used as 
visual stimulation to endorse oral fluid tests as a more user-friendly version of and an 
attractive alternative to conventional HIV testing.  The poster campaign will aim to: 
 
o positively influence the public perception of HIV oral tests and testing; 
o educate and inform the general public on the advantages of the oral fluid rapid 
test; 
o persuade those who have any kind of aversion towards a blood HIV test to test 
for HIV by using oral fluid tests; and 
o eradicate any misconceptions that anyone might have about using oral fluid to 
test for HIV. 
 
 
The findings in this report also suggest that public opinion of those who have been tested by 
lay counsellors are in favour of trained lay counsellors being allowed to administer oral rapid 
tests.  Hence, the following is suggested: 
 
 Submit and pass legislation that recognizes lay counsellors to administrate oral 
fluid testing in an official sanctioned capacity.   
 
                                                 
12  See Addendum C for a proposed poster campaign to promote oral fluid rapid HIV testing. 
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Although it is not the intention of this study to promote the administration of blood 
rapid HIV tests by lay counsellors, research by Delaney et al (2002) to determine 
whether persons with no laboratory experience could successfully perform blood 
rapid HIV tests at sites in Los Angeles, Phoenix, New York, Chicago, Atlanta, Miami 
and New Orleans in the USA, concluded that untrained, inexperienced persons: 
 
o obtained a correct result in 827 (96.6%) of 856 OraQuick® Rapid HIV-1/2 
Tests after reading only the written instructions provided by the 
manufacturer; and 
o who performed the OraQuick® Rapid HIV-1/2 Test obtained proficiency 
scores considerably higher than the 80% required by CLIA of trained 
laboratory workers. 
 
The oral fluid version of the OraQuick® Rapid HIV-1/2 Test is even more simple to 
perform than the blood rapid version, serving as further evidence that non-medically 
trained individuals should be allowed to administer the oral testing process in an 
official sanctioned capacity. 
 
This action will empower more individuals (i.e. lay counsellors) to administer HIV 
testing, as apposed to only medically trained personnel performing these tests.  Such 
legislation should only be passed on the condition that structures are in place to create 
a training standard for performing oral fluid rapid tests that would be compulsory for 
lay counsellors to successfully complete before administering these tests. 
 
 
In the Department of Health’s document, HIV/AIDS Policy Guideline: Rapid HIV Testing, 
mention is made that rapid tests are not necessarily easy to perform or interpret.  Adequate 
training and experience is necessary before health care workers use these tests.  Quality 
control procedures should be instituted to ensure that test kits are stored and conducted in a 
proper manner.  Strict stock control should also be instituted to ensure that test kits are 
properly accounted for.   
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The document goes on to say that the HIV/AIDS and STD Directorate recommend that a 
quality assurance (QA)13 process be implemented to evaluate and monitor test kit 
performance, as well as to ensure that suitably trained personnel are monitored in the correct 
use of these kits and that these kits are approved. 
(Department of Health (b), 2000).   
 
Currently no QA process is in place for the use of the OraQuick® Rapid HIV-1/2 Test for 
oral fluid.  Although oral tests are relatively easy to carry out, it is essential to have structures 
in place to make sure that all parties involved receive proper training in the workings of these 
tests.  This would guarantee the accountable distribution, application and management of oral 
tests, thereby creating a standard of excellence that has to be adhered to when facilitating any 
aspect of oral fluid testing.   
 
 
If lay counsellors are permitted to administer these tests, it makes it even more essential to 
institute such regulations enforcing quality control for oral testing administrators and VCT 
sites.  Consequently, the following recommendation is made: 
 
 Develop QA guidelines for the use of the OraQuick® Rapid HIV-1/2 Test for 
oral fluid. 
 
This research project proposes QA guidelines14 for testing using the OraQuick® Rapid 
HIV-1/2 Test for oral fluid.  These guidelines outline the basic processes and 
procedures that should be in place before a site offers oral fluid rapid HIV testing.  It 
describes steps that could be taken to identify and prevent errors in the testing 
process.   
                                                 
13  QA refers to planned, step-by-step activities that let one know that testing is being carried out correctly, 
results are accurate, and mistakes are found and corrected to avoid adverse outcomes.  It is an ongoing set of 
activities that help to ensure that the test results provided are as accurate and reliable as possible for all persons 
being tested.  QA activities should be in place during the entire testing process; this means from the time a 
person asks to be tested until the test result is provided (CDC (b)). 
 
14  See Addendum B for the Proposed Quality Assurance (QA) Guidelines for Oral Fluid Rapid 1/2 HIV Testing 
document.  It is based on the Quality Assurance Guidelines for Testing using the OraQuick® Rapid HIV-1 
Antibody Test from the Centres for Disease Control and Prevention (CDC (b)).   
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QA guidelines should preferably be initiated, developed and implemented in 
collaboration with the Department of Health.  This is an essential step to help lay the 
foundation for creating a benchmark of quality so as to ensure the responsible use and 
administration of these tests.  
 
Implementing oral fluid testing on a countrywide scale to increase HIV testing is, at present, 
not a viable venture.  The cost of the OraQuick® Rapid HIV-1/2 Test for oral fluid cannot 
currently compare to that of finger-prick rapid HIV tests, which are much cheaper to use (D. 
Ritson,15 personal communication, 16 November 2004).   
 
The OraSure® HIV-1 Oral Specimen Collection Device is also expensive, and this was one 
of the main reasons for not using this test again in the second Nelson Mandela/HSRC Study of 
AIDS that was launched on November 8, 2004.  It was decided to rather use dry blood spot-
tests for the second study (M. Colvin,16 personal communication, 12 November 2004).   
 
Furthermore, the regular availability of the OraQuick® Rapid HIV-1/2 Test has proven to be 
problematic, for example for institutions like the MRC (D. Makhubela,17 personal 
communication, 12 November 2004).  Therefore, it could be difficult to deploy these tests at 
a national level. 
 
 
Yet, this research project has shown that the lack of the need for a blood specimen in oral 
fluid testing can positively influence testing for HIV, and does have a role to play in SA.  
Hence, the following more affordable and feasible way is suggested to promote HIV oral 
fluid testing: 
 
 Set up mobile HIV/AIDS testing units promoting HIV testing using oral fluid. 
 
                                                 
15  Diane Ritson is MD of PeopleManagement, a HIV/AIDS consultancy based in Cape Town, SA. 
 
16  Dr Mark Colvin is the senior research associate for CADRE, affiliated with the MRC & HSRC in SA. 
 
17  Dennis Makhubela is associated with the MRC HIV Prevention Unit in Durban, SA. 
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The following plan of action is suggested: 
 
o Negotiate the buy-in from relevant role players (for example the Department 
of Health, OraSure Technologies, Inc. and private concerns) to generate the 
necessary resources and manpower for the project. 
o Depending on the financial backing obtained for the venture, decide on the 
number of mobile units to organize.  
o Make a decision on how many lay counsellors to select for managing these 
mobile testing units. 
o Select the lay counsellors for the undertaking. 
o Set up and organize workshops for the training of the lay counsellors on how 
to manage the mobile testing units.   
o Decide on training themes for the workshops, for example, how to 
administrate oral testing and how to set up a platform for quality control.18   
o Decide on target areas and plan a mobile clinic road show accordingly (high 
risk, resource limited communities could, for example, be targeted).    
o Make the mobile units visually striking, prominent and eye-catching by 
covering them with pictures and slogans19 promoting oral fluid HIV testing in 
terms of the advantages it offers as result of the lack of the need for a blood 
specimen. 
o Customize the mobile units for oral fluid HIV testing, making it as convenient 
as possible, without jeopardizing confidentiality.  
o Include a counselling room in these units for pre- and post-test counselling 
sessions. 
o Develop a resource list for the specific intervention areas that will serve as an 
information brochure for people on what to do after testing and receiving their 
results.  This document must advise individuals where and how to consult and 
obtain information about HIV/AIDS care and support systems in their specific 
community (for example where to go for a confirmatory test, the closest 
hospitals, clinics, etc.). 
                                                 
18  See Addendum B for the proposed QA guidelines. 
 
19  See Addendum C for the proposed poster campaign. 
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o Plan an official launch and involve the media, all relevant stakeholders and the 
public. 
 
 
9 CONCLUSION  
In summary, the findings and proposed recommendations of this research project stipulates 
that: 
 
 The lack of the need for a blood specimen in oral fluid testing offers a fresh, new and 
innovative way to persuade at-risk individuals to get tested for HIV. 
 The profile, image and public awareness of oral fluid testing in SA need to be 
improved. 
 QA guidelines should be developed and put in place for oral fluid HIV testing in 
South Africa. 
 Trained lay counsellors should conduct oral fluid HIV testing and counselling in an 
official sanctioned capacity by means of a mobile unit road show.  It is believed that 
such actions will help to take the load off already stretched medical services and 
create additional resources to, for example, more readily access remote urban and 
rural areas of SA to conduct HIV testing. 
 
The abovementioned actions should lay the platform for successfully promoting and boosting 
HIV testing in general, while at the same time creating additional opportunities to get tested.  
These actions would have a trickle-down effect on the number of individuals knowing – and 
owning – their HIV status. 
 
A lot of excitement vis-à-vis oral fluid HIV testing currently exists in the USA: 
 
 The White House announced its continued support for efforts to promote prevention 
while encouraging research to combat HIV/AIDS in 2004.  These efforts include 
encouraging testing: approximately 40,000 Americans become infected with this 
disease each year.  The White House endorsed the FDA’s action to facilitate in this 
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effort by approving the quicker and less invasive OraQuick® Rapid HIV-1/2 Test for 
oral fluid.   
(White House, 2004) 
 
On June 23, 2004, American President George W. Bush visited Philadelphia in 
Pennsylvania to discuss the need for providing treatment to Americans living with 
HIV/AIDS, and to highlight the work of faith-based and community organizations as 
they seek to treat and care for Americans living with HIV/AIDS.  In his speech, Bush 
said: 
 
Testing (for HIV) now is easier than ever.  My administration is encouraging health 
care providers to test for HIV routinely, to save lives, that's why we're doing that.  
For the sake of their health and for the sake of the health of others, I urge all 
Americans at risk to get the test.  By getting the test, you'll be making a significant 
contribution to making sure that we arrest the spread of HIV/AIDS. 
(White House, 2004) 
 
 On December 1, 2004, OraSure Technologies, Inc. opened the NASDAQ Stock 
Market in recognition of World AIDS Day.  OraSure President and CEO, Douglas A. 
Michels, presided over the NASDAQ Market Open ceremony in New York City, 
USA.  In his speech, Michels said: 
 
"In order to help control HIV/AIDS and provide treatment to those in need, it is 
critical that individuals who may be infected learn their HIV status.  We believe the 
OraQuick® ADVANCE Rapid HIV-1/2 Antibody Test is the most versatile and 
comprehensive rapid HIV test available and are committed to making the test 
available to the widest possible range of customers in the United States and abroad." 
 
In recognition of World AIDS Day 2004, major cities across the USA are launching 
rapid oral fluid HIV testing initiatives with OraQuick® ADVANCE Rapid HIV-1/2 
Antibody Test in conjunction with World AIDS Day activities.  
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The manufacturers of the FDA approved oral tests, OraSure Technologies, Inc. have 
indicated that they are considering ways to readdress their test pricing structure to make it 
more affordable in SA (Q. Pham, personal communication, 28 October 2004).  Therefore, the 
future promotion of oral HIV testing on a larger scale in this country (similar to what is 
currently the case in the USA as discussed above), is not improbable.   
 
In the long run, the minimal training required to administer oral tests and the lack of the need 
for specialized facilities (for example laboratories) and additional testing devices (for 
example blood lancets for finger-prick HIV/AIDS tests) associated with these tests, could 
also contribute to bringing down the costs involved. 
 
In an era where the emphasis is on expediency in all aspects of our lives, the use of oral fluid 
brings the HIV testing process – through its effortlessness and simplicity - in line with this 
modern day expectation.  This aspect, therefore, makes it so much more important to never 
forget that the testing at issue here is testing for HIV/AIDS - a disease that continues to have 
a social and cultural impact far beyond the number of people infected. 
 
&*&*&*&*&*&*&*&*&*&*&*&*&*&*& 
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ADDENDUM A 
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This questionnare is to get your thoughts on the Oraquick oral fluid rapid HIV tests used in the recent HIV and Aids campaign.  
This is for a joint research project between PeopleManagement (the company who facilitated the HIV and Aids training and testing intervention) and the University of Stellenbosch.  
Please complete it, even if you did not test.    It is completely voluntary, anonymous and confidential.  Thank you very much for your co-operation.  
>40
Undecided
Blood or Oral specimen.  
It doesn't really matter.
Please indicate the extent of your agreement or disagreement
with the statements below.
Do this by placing a tick in the appropriate column. 
3. Because of the noninvasive nature of oral testing,
     more individuals will be willing to test for HIV.  
4.  Because there is no fear of needles and blood involved in oral testing,
     more individuals will be willing to test for HIV.  
5. Because there is no safety risk of HIV transmission through blood in oral testing,
    more individuals will be willing to test for HIV.  
6. Because oral fluid tests are just as accurate in correctly determining your HIV status
    without taking blood, more individuals will be willing to test for HIV.  
7. Because oral fluid tests are just as reliable in consistently giving the same HIV test result
     without taking blood, more individuals will be willing to test for HIV.  
8. Because no specialist blood taking procedure is involved in oral testing,
    non-medical personnel, trained in performing the oral HIV test,
    can be allowed to conduct the testing process.
2. If you had to make the following choice:       
Would you prefer to test for HIV by giving a ...  
strongly 
disagree
neither 
agree nor 
disagree
1. Did you perceive the use of oral tests to test 
for HIV as a success?  Yes No
disagree
Blood 
specimen Oral specimen
strongly 
agree agree
GENDER Male Female
Oral HIV and Aids Test Questionnare
Please indicate your:
Place a tick in the appropriate column:
AGE <30 30 - 40
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Proposed Quality Assurance (QA) Guidelines for Testing 
using the OraQuick® Rapid HIV-1/2 Test for Oral Fluid 
 
 
Introduction
 
Summary of Basic Elements of a QA Programme  
for the OraQuick® Rapid HIV-1/2 Test for Oral Fluid 
Even though the OraQuick® Rapid HIV-1/2 Test for oral fluid is simple to use, things can go 
wrong.  To help find and prevent problems, the basic elements of a quality assurance (QA) 
programme should be in place before offering testing.  These basic elements are the corner 
stones of a QA programme and are listed below.  More detail on these five elements is 
provided in this document. 
1. Organization of the QA programme  
2. Testing personnel  
3. Process control  
a. Before testing  
b. During testing  
c. After testing  
4. Documents and records  
5. Troubleshooting 
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Organization of the QA programme 
Establishing a QA programme 
Someone must oversee the programme and ensure that the necessary staff and supplies are 
available.  Each organization must: 
 identify the person(s) responsible for managing the QA programme (this could be 
a senior staff member, outside consultant or a network of individuals who oversee 
different aspects of the QA programme);  
 write procedures (step-by-step instructions) and make them available to all staff 
involved in testing;  
 verify the testing process;  
 ensure staff know how to perform processes and procedures (see the section on 
personnel who conduct testing); and 
 create mechanisms for communication so that those who need to know are 
informed about QA issues, as well as all staff, when appropriate.  
Verifying the testing process 
Before offering the test to clients or patients, each site should make sure (verify) that the 
testing process works as planned.  This verification should be completed before testing is 
offered.  Verification includes ensuring that staff have been trained and are able 
(competent) to perform their assigned tasks, the test kits work as expected and the 
logistics for providing confirmatory testing (if a person tests positive, he or she still has to 
have a test to confirm the finding) are in place.  
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Providing written procedures 
It is strongly recommended that step-by-step, written instructions be made available to all 
staff performing testing.  This will help to ensure that they know how to perform specific 
tasks and testing success is not left to chance.  Testing personnel must follow instructions 
provided by the manufacturer.  Additional procedures, as listed below, should be provided 
along with the manufacturer’s instructions.  Text from the current OraQuick package insert 
may be used for some of the items denoted by an asterisk (*) in the list below.  Written 
instructions should describe how to: 
 train new employees; 
 assess their ability to do the testing and document training;  
 provide information to persons being tested before testing;*  
 maintain sufficient supplies;  
 check that tests and control kits have not yet expired;  
 follow the manufacturer’s instructions for storage;  
 check performance of new test kit lots (a test kit lot is defined as the boxes of test 
devices that contain either 25 or 100 tests that have the same lot number labeled 
on the outside of the boxes) and shipments; 
 perform quality control testing and take action if controls don’t work;  
 collect the OraQuick specimen; *  
 perform steps in the test procedure; *  
 report results;  
 refer persons being tested for confirmatory testing where necessary; 
 record test and quality control results;  
 conduct external quality assessment; 
 review records and store and destroy them when they are outdated; and 
 take corrective action when things go wrong.  
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Testing Personnel 
Overview 
Having qualified, trained staff to perform and supervise OraQuick testing and the various 
activities in the QA programme is one of the most important factors for ensuring accurate and 
reliable results.  Key aspects of this element include: 
 Qualifications 
 Training 
 Competency assessment (i.e. how well they are doing their job)  
Personnel qualifications 
It is recommended that certain qualities be considered when selecting personnel to perform 
the OraQuick® Rapid HIV-1/2 Test for oral fluid.  The following list of qualities resulted 
from practical considerations and expert opinion: 
 Sincerity and commitment – A dedication to performing testing according to 
defined procedures.  
 Literacy – The ability to read instructions and record results is critical.  
 Organizational skills – The need for this quality will depend on the number and 
complexity of tasks an individual performs in the testing process.  If test volume is 
high and the individual performing testing is doing several tests or managing 
several other tasks simultaneously, organizational skills can be critical.  
 Decision-making skills – Testing personnel should be able to interpret results and 
be able to recognize and handle problems that might crop up.  
 Communication skills – If the person performing the test also is the one who 
shares results or other information with the person being tested, being able to 
communicate clearly is important.  
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Components of training 
Training is crucial to ensuring quality testing.  Staff should be fully trained on how to 
perform their assigned tasks and responsibilities.  Training should be documented for each 
staff member.  The key components to include in a training programme are: 
 how to perform the test, including procedures performed before, during and after 
testing;  
 how testing is integrated into the overall counselling and testing programme; and 
 the importance of QA and the elements of the site’s QA programme.  
Training method 
Training method should optimally include the following activities: 
 Read the instructions for performing the test.  
 Watch someone perform the test or view a video of someone performing the test.  
 Practice performing the test with positive and negative control materials.  
 Review the procedures and forms on how to document testing.  
 Update counselling skills, focussing on updating counselling skills specifically 
relevant to single-session counselling used in conjunction with rapid HIV testing. 
Competency assessment 
Before a trainee is permitted to perform testing alone for the first time, his or her ability to 
conduct the test should be demonstrated and documented.  A supervisor or trainer should 
perform the assessment, using a combination of methods to determine competency.  
Examples of these methods are presented below. 
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Assessing performance of tasks done before testing 
To assess the task performance before testing, staff should be observed as they: 
 run the external controls and record results; and 
 set up the testing area, label the device and prepare control & test results sheets.  
Assessing performance of tasks done during testing 
To assess staff’s ability to perform the test and interpret results: 
 Observe the staff member performing the oral test.   
 Observe how the test is performed on a client/patient.  If such observation 
interferes with actual client-provider interactions, observe test performance on a 
volunteer.  
 Appraise the individual’s ability to interpret results.  This might include utilizing 
previously used test devices or pictures of devices that show non-reactive, weakly 
reactive, reactive and invalid results.  
Assessing performance of tasks done after testing 
To assess task performance after testing: 
 Review test records and quality control results documentation.  
 Observe oral reporting of results to a test subject (if trainee’s responsibility).  
 Observe the handling of procedures for confirmatory testing referral.  
 Verify that confidentiality is maintained. 
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Process Control
 
What is process control? 
Process control refers to the activities and techniques that are carried out to ensure that the 
testing procedures are performed correctly, the environment is suitable, and the test kit works 
as expected to produce accurate and reliable results.
 
Steps in the testing process 
Steps in the testing process follow the path of workflow beginning with tasks before testing, 
followed by those conducted during and after testing.  This path of workflow and the 
associated steps are shown in the table below.  Detailed descriptions about each of the steps 
listed in this table are provided in the remainder of this document. 
 
 
Before testing  During testing After testing 
 Check storage temperatures 
 Check inventory and test kit lots, as needed  
 Receive request for testing  
 Provide HIV/AIDS information to the test 
subject  
 Set up test area, label test device  
 Perform external quality control according to the 
manufacturer’s and the site’s instructions  
 Perform the test 
 Interpret test 
results  
 Report results to client  
 Document results  
 Participate in external 
quality assessment 
(periodically)  
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Before Testing 
 
Overview 
As shown in the table above, there are a number of steps that must be followed before testing 
the oral fluid sample for HIV.  These activities are in place to ensure that the conditions in 
which the tests are stored and performed are suitable, the test area and the test subject are 
prepared, and the test is working appropriately. 
 
Temperature control 
Test kits must be stored in an environment within the temperature ranges specified by the 
manufacturer.  Store test kits at 2° to 30° C.  Perform tests at 15° to 27°C.  If the test must be 
performed at a temperature below 15°C or above 27°C, run external controls that have been 
stored within the proper temperature range to find out if the test can be performed at another 
temperature. 
 
Checking inventory and test kits 
Procedures should be in place to ensure that an adequate supply of unexpired test kits, 
controls, and supplies is available.  Test kits and controls have a defined shelf life.  Use the 
oldest first.  Never use test or control kits beyond their expiration dates.  It is helpful to use a 
log sheet to document when test and control kits are received, their lot numbers and 
expiration dates.  As described in the package insert and in the section on quality control 
below, run the positive and negative controls with new lots and new shipments of test kits 
before using them for testing (i.e. to verify that they work as expected).
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Setting up the testing area and labeling the test device 
Before testing, the testing area should be prepared according to the specific site procedure, 
which should include directions for setting up the workspace listed in the test kit instructions, 
as well as instructions for how to label testing devices and complete report forms, including 
the method for identifying each person to be tested to ensure specimens are not mixed up 
during the testing process.  Labeling is especially important when more than one test is being 
performed at the same time.  Label components of the test with the name or identifying 
number of the person being tested before collecting the specimen.  These components include 
the developer solution vial, test device, and documents for recording results.  Using pre-
printed labels improves the efficiency of performing this task. 
Note: Do not place a label over the two holes on the back of the test device as this can cause 
an invalid result. 
 
Providing information to test subjects 
It is important to explain how the test works to each person being tested prior to performing 
the test.  This can also be done in the pre-test counselling session.
 
Quality control 
There are two types of quality control (QC) for the the OraQuick® Rapid HIV-1/2 Test for 
oral fluid.  These are described in the table below. 
Type of quality control Description of activity
Internal Controls A control is built in to each testing device to verify that the specimen was 
adequate and the solution flowed through the device as intended. 
External Controls Known reactive and non-reactive specimens (controls) are available from the 
manufacturer to sites purchasing this test.  They are used to evaluate the 
accuracy of the test in detecting antibody to HIV and to check if the person 
conducting the test performs it correctly. 
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External quality control 
To verify that the test device is accurately detecting HIV-1 antibodies, external controls must 
be tested from time to time.  The test kit manufacturer provides external controls and can be 
ordered separately from the test kit.  How often controls are run to verify the accuracy of the 
test will depend on the number of tests carried out by the site, how often new test kit 
shipments or lot numbers are received by a site, and how often staff who conduct the testing 
change.  
The manufacturer has set guidelines for the running of external controls.  The test kit 
instructions specifies running controls under the circumstances below.  Run controls: 
 prior to a new operator performing testing on patients;  
 whenever two consecutive invalid test results are obtained on a person being tested; 
 when opening a new test kit lot or a new shipment of test kits is received (even if it is 
the same kit lot number in current use);  
 if the temperature of the test storage area falls outside of 2°-30° C;  
 if the temperature of the testing area falls outside of 15°-27° C; and  
 at periodic intervals as dictated by the user facility.  
 
Frequency of running external controls on the basis of test volume 
When external controls provide incorrect results, none of the tests that were run since the last 
time control results were correct can be considered valid.  This means that everyone who was 
tested since the last time controls ran correctly will need to be called back and retested, which 
is not practically possible.  Sites testing large numbers of persons, and especially those that 
offer anonymous testing, should plan to run controls more often than facilities that conduct 
fewer tests.  Facilities that test 25 or more subjects a day should run controls every day.  Low 
volume sites, such as those testing fewer than 25 subjects per month, should run external 
controls every two to four weeks at a minimum.  
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During Testing 
 
Overview 
This phase of the testing process involves running the test and interpreting the results. 
Activities during testing include collecting the specimen, performing the test and interpreting 
the internal control and client/patient test results.
 
Collecting, performing and interpreting test results 
Follow the written procedure for oral specimen collecting, performing and interpreting the 
results.  Results can be one of the following: 
 Nonreactive (negative)  
 Reactive (preliminary positive)  
 Invalid (the test result is inconclusive and cannot be interpreted; see below for 
information on handling invalid results)  
 
Evaluating internal control results 
Each test device includes a built-in (internal) control.  When an appropriate line develops at 
the center of the “C” location on the device, the patient’s specimen has been correctly loaded 
and has traveled through the test strip, indicating a valid test.  Additional information is 
provided in the test kit package insert.  These controls are included in every device, and 
control results are evaluated with every test.  If the internal control does not produce the 
expected result, the test result for the patient is not valid, cannot be reported, and the test must 
be repeated.  If a second invalid result occurs, external controls should be evaluated as 
described below before repeating the test a third time.
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After Testing 
 
Overview 
Quality assurance extends to those activities completed following the performance of the test.  
Each site should have established procedures for: 
 reporting and recording results;  
 referral procedure for test subjects for confirmatory testing; and 
 conducting external quality assessment.  
 
Giving Results 
This entail how results are provided to the person being tested and how results are 
documented in the test result logs.  This may differ from site to site.
 
Referral for Confirmatory Testing 
Whenever the test result is reactive (preliminary positive), a confirmatory test must be 
performed using a blood HIV test to confirm that the person being tested is infected with 
HIV.  Therefore, each site must have established procedures for referral of persons having to 
go for confirmatory testing.
 
Follow up Testing for Negative and Indeterminate Confirmatory Results 
Some test results may be negative or indeterminate.  If the confirmatory test result is 
negative, specimen mix-up needs to be ruled out versus a false positive result.  It is 
recommended that the confirmatory test be repeated.
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Managing confirmatory results 
OraQuick testing sites that refer specimens for confirmatory testing should have established 
procedures describing how to: 
 match the client’s/patient’s confirmatory test results with their results to find 
potential discrepancies and to ensure that testing was performed according to 
protocol;  
 report the test result to the person being tested; and  
 obtain any additional specimens needed to resolve potential specimen mix-up and 
for retesting, as needed.  
 
Handling result discrepancies 
Procedures should describe how to handle result discrepancies when the test result was 
reactive and the confirmatory test negative or indeterminate.  If the laboratory providing 
confirmatory testing performed by one confirmatory test only and reported a non-reactive or 
negative result, the testing site should contact the confirmatory testing laboratory and request 
a different confirmatory test.  If the original specimen is not available, a new specimen will 
need to be collected from the person in question to be used for confirmatory testing.
 
External assessment 
External assessment can look at how testing is being performed and whether it is being 
performed reliably.  Some external assessment mechanisms include: 
 comparing the reactive results with the confirmatory test results;  
 arranging for someone outside the organization to observe testing; and 
 participating in a proficiency testing or external evaluation programme. 
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Documents and Records 
 
Overview 
Sites using the OraQuick® Rapid HIV-1/2 Test for oral fluid should have policies and 
procedures describing what QA records are required and how and when they are reviewed, 
stored and destroyed.  Having a supervisor review records periodically is recommended. QA 
records include the following: 
 Training documentation  
 External control result logs  
 Test result logs 
 
Training documentation 
Training documents should keep record of how the trainee performs each objective or 
procedural step, as applicable.  This should include: 
 reading the test procedure;  
 determining if requirements for acceptable testing environment are met;  
 practicing the test with external controls; 
 giving person getting tested the “Subject Information” brochure;  
 labeling test device components and appropriate paperwork;  
 inserting the test device, keeping time & reading the result; 
 recording results on report forms and log sheets;  
 recording internal and external quality control (QC) results in QC log;  
 evaluating new OraQuick test kit lots; 
 numbering and recording results in QC log;  
 reporting test results to the person being tested; and  
 explaining what to do if QC results show a problem. 
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External control result logs 
External control records should include the:  
 date and time of control testing;  
 lot number and expiration of the test kit;  
 lot number and expiration date of the controls; and  
 control results, and corrective action taken if control results are unacceptable.  
Control records should be kept in the order in which they were completed so they can be 
easily compared with the test records.  This will help find answers if there are questions about 
testing performed within a specific time frame. 
 
Test result logs 
Test result records should include the date and time of testing, an identifier for the person 
being tested, a test kit lot number and expiration date, test result, action taken if the result was 
invalid and the identification of the person who performed the test, whether confirmatory 
testing was requested and the confirmatory test results when they are available.
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Troubleshooting 
 
Overview 
Each site should have a method to detect and resolve problems that occur at any point in the 
testing process, especially those that may affect the accuracy of test results.  Significant 
problems should be immediately reported to the appropriate supervisory personnel. 
 
Procedures 
Procedures should be available to all testing personnel for the following: 
 When to discontinue testing, e.g., when the external control results are 
unacceptable as described in the package insert.  
 How to take corrective action, or an action taken in response to a problem.  
 How to document problems and actions taken.  
 How to verify the corrective actions taken addressed the problem.  
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ADDENDUM C 
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